Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Azitra Inc ( (AZTR) ) has shared an announcement.
Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology therapies for severe skin conditions such as Netherton syndrome and EGFR inhibitor–associated rash, develops live biotherapeutic candidates ATR-12 and ATR-04 from its AI-supported microbial engineering platform. The company targets high-need dermatologic markets where few or no approved treatment options currently exist.
On March 5, 2026, Azitra announced it had canceled its special meeting of stockholders, which was originally convened on February 6, 2026 but adjourned to March 6, 2026 after failing to reach a quorum. The company subsequently withdrew the proposals slated for shareholder consideration, signaling a pause on the corporate actions that had been scheduled for a vote and removing an immediate governance milestone from its near-term agenda.
The most recent analyst rating on (AZTR) stock is a Sell with a $0.18 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.
Spark’s Take on AZTR Stock
According to Spark, TipRanks’ AI Analyst, AZTR is a Underperform.
The score is driven down primarily by weak financial performance (large ongoing losses, heavy cash burn, and extreme 2025 deterioration). Technicals also weigh negatively with a sustained downtrend versus key moving averages and negative MACD. Valuation provides little support due to a negative P/E and no dividend.
To see Spark’s full report on AZTR stock, click here.
More about Azitra Inc
Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology therapies. Its lead program, ATR-12, uses an engineered strain of S. epidermidis to treat Netherton syndrome, a rare and potentially fatal chronic skin disease with no approved therapies, and is being evaluated in a Phase 1b trial in adult patients.
The company’s ATR-04 program employs another engineered S. epidermidis strain to address EGFR inhibitor–associated rash, a condition affecting roughly 150,000 people in the U.S. ATR-04 has an open IND and Fast Track designation from the FDA, and both programs draw on Azitra’s AI-enabled platform built around a microbial library of about 1,500 bacterial strains.
Average Trading Volume: 1,261,948
Technical Sentiment Signal: Sell
Current Market Cap: $3.07M
Find detailed analytics on AZTR stock on TipRanks’ Stock Analysis page.